Upfront ICIs May Enhance Second-Line Responses in NSCLC Upfront ICIs May Enhance Second-Line Responses in NSCLC
Second-line ramucirumab and docetaxel after use of immune checkpoint inhibitors may improve some outcomes for patients with NSCLC. The study was published as a preprint and has not yet been peer reviewed.First Look
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Docetaxel | Hematology | Non-Small Cell Lung Cancer | Study | Taxotere